

Key Topics Covered:

Part I: Leukemia

- 5.1 The Scope of this Report 29
- 6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
- 8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
- 9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
- 11 Disclaimer 1130
- 12 Drug Index 1131
- 13 Company Index 1140
- Figures: Includes 6 Figures
- Tables: Includes 253 Tables
- Total Number of Pages: 1,147

Part II: Antibodies

- 5.1 The Scope of this Report 35
- 6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
- 7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
- 8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
- 10 Disclaimer 2361
- Figures: Includes 7 Figures
- Tables: Includes 355 Tables
- Total Number of Pages: 2,361

Part III: Peptides

- 5.1 The Scope of this Report 27
- 6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
- 7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
- 8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
- 9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388

10 Selecting Indication for Peptide Drugs in Oncology (62 Cancer Indications) 391-475

11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001

12 Disclaimer 1002

Figures: Includes 5 Figures

Tables: Includes 232 Tables

Total Number of Pages: 1,013